Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!

The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...

John Philip Jones net worth and biography

John Jones Biography and Net Worth

CFO of Alimera Sciences

Mr. Jones has been our Chief Financial Officer since January 2, 2019. From August 2016, he served as the Company’s VP Finance and Assistant Corporate Secretary and joined Alimera in June of 2015 as Corporate Controller. Prior to Alimera, Mr. Jones held various senior financial leadership roles in Theragenics Corporation, a medical product manufacturing company, Superior Essex, a communications cable company, and Arjo Wiggins Medical, the medical materials division of Arjo Wiggins Appleton. Mr. Jones began his financial career in 1986 as an accountant for a large regional CPA firm in Atlanta, Georgia. Mr. Jones is a Certified Public Accountant in the state of Georgia and is a graduate of Auburn University with a B.S.B.A. degree with an emphasis in accounting.

How do I contact John Philip Jones?: The corporate mailing address for Mr. Jones and other Alimera Sciences executives is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. Alimera Sciences can also be reached via phone at (678) 990-5740 and via email at [email protected]. Learn More on John Philip Jones' contact information.
Has John Philip Jones been buying or selling shares of Alimera Sciences?: John Philip Jones has not been actively trading shares of Alimera Sciences in the last ninety days. Most recently, on Wednesday, November 3rd, John Philip Jones bought 5,000 shares of Alimera Sciences stock. The stock was acquired at an average cost of $4.08 per share, with a total value of $20,400.00. Learn More on John Philip Jones' trading history.
Who are Alimera Sciences' active insiders?: Alimera Sciences' insider roster includes Philip Ashman (COO), Richard Eiswirth, Jr. (CEO), John Jones (CFO), and James Largent (Director). Learn More on Alimera Sciences' active insiders.
Are insiders buying or selling shares of Alimera Sciences?: During the last year, Alimera Sciences insiders bought shares 2 times. They purchased a total of 1,980,901 shares worth more than $4,346,041.70. The most recent insider tranaction occured on September, 14th when Major Shareholder Caligan Partners Lp bought 579,000 shares worth more than $1,962,810.00. Insiders at Alimera Sciences own 31.4% of the company. Learn More about insider trades at Alimera Sciences.
Information on this page was last updated on 9/14/2023.

John Philip Jones Insider Trading History at Alimera Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2021	Buy	5,000	$4.08	$20,400.00
12/10/2019	Buy	1,000	$9.44	$9,440.00

John Philip Jones Buying and Selling Activity at Alimera Sciences

Alimera Sciences Company Overview

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Today's Range

Now: $3.56

$3.55

$3.63

50 Day Range

MA: $3.71

$3.25

$4.21

2 Week Range

Now: $3.56

$1.56

$4.38

Volume

7,619 shs

Average Volume

76,498 shs

Market Capitalization

$186.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18